2008

• Strativa Pharmaceuticals in-licenses ONCONASE^® from Alfacell Corporation and oral thin film formulation of ondansetron from MonoSol Rx^®

• Par introduces five new generic products and, with its partner companies, files 10 ANDAs including seven potential first-to-files.
• Par receives approval for and launches propranolol extended release capsules, a generic version of Inderal LA^®. Par’s was the first generic version of this modified release product to be approved and reach the marketplace.
• Par in-licenses three proprietary products in development, Zensana™ (odansetron HCL) Oral Spray, Loramyc™ (miconazole Lauriad^®) and pafuramidine maleate, each aimed at building the company's portfolio of supportive care therapies for cancer and AIDS.

2006

• Par introduces nine new generic products and, with its partner companies, files six ANDAs including five potential first-to-files.
• Par begins shipment of generic Toprol-XL^® (metoprolol succinate extended release 25 mg tablets).
• Patrick G. LePore named president and chief executive officer of Par Pharmaceutical Companies, Inc.™.
• Par begins shipment of generic Flonase^® (fluticasone) Nasal Spray.

2005

• Par introduces 15 new generic products and, with its partner companies, files 17 ANDAs including one potential first-to-file.
• Par launches first specialty brand, Megace^® ES (megestrol acetate).
• Par receives approval and 180-day marketing exclusivity for generic Ultracet^®.

2004

• Par introduces 17 new generic products and, with its partner companies, files 24 new ANDAs, one first-to-file, and two NDAs.

2003

• Par begins shipment of generic Paxil^® (paroxetine HCL immediate release tablets)

2002

• Par wins prestigious DIANA Award from Healthcare Distribution Management Association

2001

• Par begins shipment of generic Megace^® and generic Prozac^® 40 mg capsules.

1987

• PRX listed on New York Stock Exchange

1978

• Par Pharmaceutical founded